COEP
Price
$12.66
Change
-$0.66 (-4.95%)
Updated
Aug 28 closing price
Capitalization
61.03M
YMAB
Price
$8.54
Change
-$0.01 (-0.12%)
Updated
Aug 28 closing price
Capitalization
388.04M
69 days until earnings call
Interact to see
Advertisement

COEP vs YMAB

Header iconCOEP vs YMAB Comparison
Open Charts COEP vs YMABBanner chart's image
Coeptis Therapeutics Holdings
Price$12.66
Change-$0.66 (-4.95%)
Volume$33.57K
Capitalization61.03M
Y-mAbs Therapeutics
Price$8.54
Change-$0.01 (-0.12%)
Volume$1.88M
Capitalization388.04M
COEP vs YMAB Comparison Chart in %
Loading...
COEP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
YMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
COEP vs. YMAB commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COEP is a Buy and YMAB is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (COEP: $12.66 vs. YMAB: $8.54)
Brand notoriety: COEP and YMAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: COEP: 66% vs. YMAB: 184%
Market capitalization -- COEP: $61.03M vs. YMAB: $388.04M
COEP [@Biotechnology] is valued at $61.03M. YMAB’s [@Biotechnology] market capitalization is $388.04M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.52B to $0. The average market capitalization across the [@Biotechnology] industry is $1.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

COEP’s FA Score shows that 0 FA rating(s) are green whileYMAB’s FA Score has 0 green FA rating(s).

  • COEP’s FA Score: 0 green, 5 red.
  • YMAB’s FA Score: 0 green, 5 red.
According to our system of comparison, YMAB is a better buy in the long-term than COEP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

COEP’s TA Score shows that 3 TA indicator(s) are bullish while YMAB’s TA Score has 5 bullish TA indicator(s).

  • COEP’s TA Score: 3 bullish, 5 bearish.
  • YMAB’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, YMAB is a better buy in the short-term than COEP.

Price Growth

COEP (@Biotechnology) experienced а -5.73% price change this week, while YMAB (@Biotechnology) price change was +0.12% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.11%. For the same industry, the average monthly price growth was +20.33%, and the average quarterly price growth was +29.99%.

Reported Earning Dates

YMAB is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+2.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
YMAB($388M) has a higher market cap than COEP($61M). COEP YTD gains are higher at: 130.182 vs. YMAB (9.068). COEP has higher annual earnings (EBITDA): -11.18M vs. YMAB (-26.3M). YMAB has more cash in the bank: 62.3M vs. COEP (2.99M). COEP has less debt than YMAB: COEP (1.33M) vs YMAB (3.12M). YMAB has higher revenues than COEP: YMAB (85.4M) vs COEP (264K).
COEPYMABCOEP / YMAB
Capitalization61M388M16%
EBITDA-11.18M-26.3M42%
Gain YTD130.1829.0681,436%
P/E RatioN/AN/A-
Revenue264K85.4M0%
Total Cash2.99M62.3M5%
Total Debt1.33M3.12M43%
FUNDAMENTALS RATINGS
COEP vs YMAB: Fundamental Ratings
COEP
YMAB
OUTLOOK RATING
1..100
128
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
42
Fair valued
PROFIT vs RISK RATING
1..100
94100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
3736
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
7550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

YMAB's Valuation (42) in the Pharmaceuticals Major industry is in the same range as COEP (69) in the null industry. This means that YMAB’s stock grew similarly to COEP’s over the last 12 months.

COEP's Profit vs Risk Rating (94) in the null industry is in the same range as YMAB (100) in the Pharmaceuticals Major industry. This means that COEP’s stock grew similarly to YMAB’s over the last 12 months.

COEP's SMR Rating (100) in the null industry is in the same range as YMAB (100) in the Pharmaceuticals Major industry. This means that COEP’s stock grew similarly to YMAB’s over the last 12 months.

YMAB's Price Growth Rating (36) in the Pharmaceuticals Major industry is in the same range as COEP (37) in the null industry. This means that YMAB’s stock grew similarly to COEP’s over the last 12 months.

YMAB's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as COEP (100) in the null industry. This means that YMAB’s stock grew similarly to COEP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
COEPYMAB
RSI
ODDS (%)
Bearish Trend 1 day ago
51%
Bearish Trend 1 day ago
81%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
46%
Bearish Trend 1 day ago
82%
Momentum
ODDS (%)
Bullish Trend 1 day ago
52%
Bullish Trend 1 day ago
88%
MACD
ODDS (%)
Bearish Trend 1 day ago
53%
Bearish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
68%
Bullish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
42%
Bullish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 5 days ago
63%
Bullish Trend 3 days ago
82%
Declines
ODDS (%)
Bearish Trend 29 days ago
77%
N/A
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
41%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
22%
Bullish Trend 1 day ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
COEP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
YMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AOZOY4.05N/A
N/A
Aozora Bank Ltd.
MRCR3.30N/A
N/A
Moro Corporation
WSOUF22.25N/A
N/A
Washington Hsoul Pattinson & Co., Ltd.
PLMUF11.18N/A
N/A
Plum Acquisition Corp. III
PDER288.00-11.55
-3.86%
Pardee Resources Co.

YMAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, YMAB has been loosely correlated with NEVPF. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if YMAB jumps, then NEVPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To YMAB
1D Price
Change %
YMAB100%
-0.12%
NEVPF - YMAB
56%
Loosely correlated
N/A
SNDX - YMAB
45%
Loosely correlated
+0.37%
COGT - YMAB
36%
Loosely correlated
-2.34%
VTYX - YMAB
35%
Loosely correlated
-2.39%
EYPT - YMAB
34%
Loosely correlated
-2.03%
More